{"filing":{"accession_number":"0001213900-26-102385","cik":"0002007702","ticker":"HKPD","company_name":"Cellyan Biotechnology Co., Ltd","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"ea0306235-6k_cellyan.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007702/000121390026102385/ea0306235-6k_cellyan.htm"},"events":[{"id":34517,"run_id":31761,"accession_number":"0001213900-26-102385","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of an extraordinary general meeting held on September 21, 2026, where shareholders voted on two matters: (1) a 1-for-20 share consolidation affecting both Class A and Class B ordinary shares, and (2) adoption of a Fifth Amended Memorandum and Articles of Association conditional on the consolidation. Both resolutions passed with overwhelming majorities (360,889,111 votes for the consolidation, 6,847 against). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it fundamentally alters share structure and par value.","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":38262,"accession_number":"0001213900-26-102385","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of an extraordinary general meeting held on September 21, 2026, where shareholders voted on two matters: (1) a 1-for-20 share consolidation affecting both Class A and Class B ordinary shares, and (2) adoption of a Fifth Amended Memorandum and Articles of Association conditional on the consolidation. Both resolutions passed with overwhelming majorities (360,889,111 votes for the consolidation, 6,847 against). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it fundamentally alters share structure and par value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T13:11:39.704420+00:00","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-09-23"}]}